Janssen buys up eye disorder gene therapy asset from Hemera Biosciences

Janssen buys up eye disorder gene therapy asset from Hemera Biosciences

Source: 
Fierce Biotech
snippet: 

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

The deal, financials of which are not being shared, is for the investigational phase 1 gene therapy HMR59, which is given as a one-and-done shot into the eye with the aim of helping preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).